Freenome Swings to $60M Profit on $183.5M Q3 Revenue After FDA Nod
FRNM is trading near its 52-week low of $9.71 (10% above the low).
Summary
Freenome's first quarter as a public company produced $183.5 million in revenue versus $1.0 million a year ago, almost all of it the $180.0 million recognized under its collaboration and license agreement after FDA approval of SimpleScreen CRC. GAAP net income was $60.1 million against a $64.5 million loss in Q3 2025, and adjusted EBITDA came in at $117.9 million. The company ended September with $430.0 million in cash and marketable securities and generated $38.4 million of operating cash flow. Full-year 2026 revenue guidance of $192 million to $194 million implies a modest fourth quarter, since nine-month revenue was already $190.0 million. Abbott launched SimpleScreen CRC in the U.S. on September 30, and Freenome expects its next two single-cancer data readouts in December, with the first asymptomatic multi-cancer readout in mid-2027.
At the time of this announcement, FRNM was trading at $10.69 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $9.71 to $17.50. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.